Achieve Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Shareholders' Equity

Consolidated Statements of Shareholders' Equity (USD $)	Total	Warrant [Member]	Common stock [Member]	Common stock [Member] Warrant [Member]	Additional paid-in capital [Member]	Additional paid-in capital [Member] Warrant [Member]	Accumulated other comprehensive income (loss) [Member]	Accumulated deficit [Member]	March 2012 Financing [Member]	March 2012 Financing [Member] Common stock [Member]	March 2012 Financing [Member] Additional paid-in capital [Member]	July 2014 Financing [Member]	July 2014 Financing [Member] Common stock [Member]	July 2014 Financing [Member] Additional paid-in capital [Member]
Beginning Balance at Dec. 31, 2011	$ 30,890,000us-gaap_StockholdersEquity		$ 10,000		$ 108,986,000		$ 2,636,000	$ (80,742,000)
Beginning Balance, Shares at Dec. 31, 2011			9,749,819
Stock-based compensation expense	2,175,000				2,175,000
Shares issued in financing									53,777,000	5,000	53,772,000
Shares issued in financing, Shares										4,789,750
Stock option exercises	462,000				462,000
Stock option exercises, Shares	117,347		117,347
Restricted Stock Unit Settlements, Shares	0
Net loss	(21,098,000)us-gaap_NetIncomeLoss							(21,098,000)
Other comprehensive income (loss)	1,000						1,000
Ending Balance at Dec. 31, 2012	66,207,000us-gaap_StockholdersEquity		15,000		165,395,000		2,637,000	(101,840,000)
Ending Balance, Shares at Dec. 31, 2012			14,656,916
Stock-based compensation expense	2,837,000				2,837,000
Stock option exercises	10,000				10,000
Stock option exercises, Shares	3,475		3,475
Restricted Stock Unit Settlements, Shares	47,495		47,495
Net loss	(31,849,000)us-gaap_NetIncomeLoss							(31,849,000)
Other comprehensive income (loss)	6,000						6,000
Ending Balance at Dec. 31, 2013	37,211,000us-gaap_StockholdersEquity		15,000		168,242,000		2,643,000	(133,689,000)
Ending Balance, Shares at Dec. 31, 2013			14,707,886
Stock-based compensation expense	3,860,000				3,860,000
Shares issued in financing	2,860,000				2,860,000							16,375,000	6,000	16,369,000
Shares issued in financing, Shares			809,214										5,559,866
Stock option exercises	30,000				30,000
Stock option exercises, Shares	10,000		10,000
Restricted Stock Unit Settlements, Shares	203,148		53,971
Performance Restricted Stock Unit Settlements, Shares			149,177
Performance Restricted Stock Unit Settlements withheld and retired to treasury	(29,000)							(29,000)
Performance Restricted Stock Unit Settlements withheld and retired to treasury, Shares			(9,226)
Warrant Exercises		13,000		1,000		12,000
Warrant Exercises, Shares				1,340,538
Net loss	(26,240,000)us-gaap_NetIncomeLoss							(26,240,000)
Other comprehensive income (loss)	(21,000)						(21,000)
Ending Balance at Dec. 31, 2014	$ 34,059,000us-gaap_StockholdersEquity		$ 22,000		$ 191,373,000		$ 2,622,000	$ (159,958,000)
Ending Balance, Shares at Dec. 31, 2014			22,621,426